FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to biotechnology. Described is an antibody or its antigen-binding fragment, which binds human ErB3. Described are expression vectors, recovered nucleic acids coding variable regions of the above antibody and host cells. The antibodies are applicable for treating diseases and disorders associated with cell proliferation, including specific malignant new growths related to ErbB3/Her3 activation.
EFFECT: disclosed are a method for inhibiting or reducing malignant cell proliferation, as well as a method for reducing tumour growths, a method for producing a peptide, and a method for treating cancer.
34 cl, 30 dwg, 22 tbl, 18 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODY AGAINST GD2-O-ACETYLATED GANGLIOSIDE WITH PRO-APOPTOTIC ACTIVITY | 2014 |
|
RU2679715C1 |
| ANTI-INTEGRIN ALPHA-2 ANTIBODIES AND USING THEM | 2011 |
|
RU2545401C2 |
| HEAVY CHAIN MUTANT RESULTING IN INCREASED IMMUNOGLOBULIN PRODUCTION | 2008 |
|
RU2522481C2 |
| HUMANISED TAU ANTIBODIES IN ALZHEIMER DISEASE | 2015 |
|
RU2730668C2 |
| HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 | 2003 |
|
RU2366664C2 |
| ANTI-c-Met ANTIBODY | 2009 |
|
RU2560257C2 |
| PROTEINS BINDING SPECIFIC MEMBRANE PROSTATE ANTIGEN, AND RELATED COMPOSITIONS AND METHODS | 2012 |
|
RU2632647C2 |
| ANTIBODIES AGAINST MYELIN-ASSOCIATED GLYCOPROTEIN (MAG) | 2003 |
|
RU2303461C9 |
| HUMAN INTERLEUKIN 17 (IL-17) ANTIBODIES AND USING THEM | 2009 |
|
RU2539029C2 |
| NEW ANTIBODY TO c-Met | 2011 |
|
RU2607377C2 |
